

# Press Release

**ProStrakan Group plc**

**ProStrakan announces successful EU MRP conclusion for Tostrex™**

**Galashiels, Scotland, 11 April 2006** - ProStrakan Group plc (LSE: PSK), the European specialty pharmaceutical company, today announces the successful conclusion of the EU Mutual Recognition Procedure (MRP) for Tostrex™. The procedure completed successfully at the “day 90” target date of 7 April 2006. Tostrex™ 2% gel is a testosterone replacement therapy for use in hypogonadal men.

The first EU launch of Tostrex™ was onto the Swedish market in September 2005. Following the conclusion of the MRP process, national licences will be issued in due course in all 19 additional countries included in the MRP submission application. Launches in these other European territories will take place during H1 2007.

ProStrakan obtained the EU marketing rights to Tostrex™ from Cellegy in July 2004 and negotiated additional rights relating to the manufacture of the product in January 2006.

Given the association between low testosterone and type 2 diabetes and cardiovascular disease, and the fact that growth in the circa \$500 million testosterone replacement market in the USA has predominantly arisen from the growth in sales of gels, Tostrex™ represents an attractive opportunity for significant near term revenue growth.

Today’s announcement follows the successful conclusion, announced on 23<sup>rd</sup> March 2006, of the MRP for Rectogesic™, ProStrakan’s 0.4% topical nitroglycerin ointment for the relief of pain associated with chronic anal fissures.

**Commenting, Dr Wilson Totten, Chief Executive of ProStrakan, said: “This second successful MRP conclusion in as many weeks confirms the value inherent in our recent product acquisitions. We are now ready for a series of new product launches across Europe later this year and through 2007, leveraging the value and effectiveness of our pan-European salesforce. We believe there is great potential in these products and look forward to increasing growth in our revenue line. ”**

**ENDS**

**For more information, please contact:**

**ProStrakan**

Wilson Totten, CEO	+ 44 (0)1896 664000
Adrian Gardner, Finance Director	+ 44 (0)1896 664000
David Watt, Corporate Comms	+ 44 (0)1896 664103

**Financial Dynamics**

David Yates/ Sarah MacLeod	+ 44 (0)20 7831 3113
----------------------------	----------------------

**Notes to Editors**

**ProStrakan**

ProStrakan Group plc is a rapidly growing international specialty pharmaceutical company engaged in the research, development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets. The company's therapeutic focus is on bone diseases, women's health and issues relating to the ageing male. Headquartered in Scotland, the company's R&D facilities are situated in Romainville, near Paris, and in Galashiels in Scotland. EU-wide sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries based in the UK, France, Germany and Spain.

ProStrakan was listed on the London Stock Exchange in June 2005.

On 23<sup>rd</sup> March 2006, the company announced its Preliminary Results for 2005: revenues up 47% to £31.6 million; gross profit up 69% to £16.7 million.

On the same day, the company made two further announcements: firstly, the in-licensing of the UK rights to Tabphyn™, a treatment for benign prostatic hyperplasia, and, secondly, the successful conclusion to the Rectogesic™ MRP (see above).

[www.prostrakan.com](http://www.prostrakan.com)